Share on StockTwits

Nektar Therapeutics (NASDAQ:NKTR) is set to announce its Q413 earnings results on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $49.26 million for the quarter.

Nektar Therapeutics (NASDAQ:NKTR) opened at 13.63 on Tuesday. Nektar Therapeutics has a one year low of $8.71 and a one year high of $14.47. The stock has a 50-day moving average of $12.51 and a 200-day moving average of $11.68. The company’s market cap is $1.583 billion.

A number of research firms have recently commented on NKTR. Analysts at Zacks downgraded shares of Nektar Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Wednesday, February 5th. They now have a $14.90 price target on the stock. On the ratings front, analysts at Brean Capital raised their price target on shares of Nektar Therapeutics from $14.00 to $18.00 in a research note on Monday, February 3rd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $14.99.

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.